Description

Everolimus is a potent and selective mTOR (mammalian target of rapamycin) inhibitor, representing a critical class of pharmaceutical active ingredients. This compound matters for its significant role in targeted cancer therapy and immunosuppression, offering a mechanism of action that is vital for modern precision medicine. It is primarily needed by pharmaceutical manufacturers and research institutions developing treatments for advanced renal cell carcinoma, breast cancer, neuroendocrine tumors, and for preventing organ transplant rejection.

Application

• Pharmaceutical Active Ingredient (API): Core component in the formulation of oral tablets and other dosage forms for targeted cancer therapies.
• Oncology Research: Used as a reference standard and investigational agent in preclinical and clinical studies targeting mTOR signaling pathways.
• Immunosuppressive Therapy: Key ingredient in medications prescribed to prevent organ rejection in transplant patients.
• Reference Standard: Serves as a high-purity standard for analytical testing, quality control, and method development in pharmaceutical laboratories.
• Drug Discovery & Development: A vital tool for biochemical and cellular assays in the discovery of new mTOR-related therapeutics.
• Academic & Institutional Research: Utilized in life science research to study cell growth, proliferation, and autophagy mechanisms.

Basic Information

Item	Detail
Product Name	Everolimus
CAS No.	159351-69-6
Molecular Formula	C53H83NO14
Molecular Weight	958.22 g/mol
Synonyms	RAD001; Afinitor; Certican; 42-O-(2-Hydroxyethyl)rapamycin; SDZ-RAD; Everolimus (USAN); Votubia; Zortress; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]-1-methylethyl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
EINECS	Contact for details

Quality Control

Our Everolimus is manufactured under strict quality management systems to ensure it meets the rigorous standards required for pharmaceutical applications. Each batch is subjected to comprehensive analytical testing, including HPLC for purity and assay, identification by spectroscopic methods, and stringent control of related substances and residual solvents. A Certificate of Analysis (COA) documenting full compliance with agreed specifications is provided with every shipment.

Storage

Preserve in a tightly closed container, protected from light. Store under an inert atmosphere (e.g., nitrogen or argon) to prevent oxidation. For long-term stability, store at a controlled room temperature of 15-25°C or as specified on the certificate of analysis. Keep the container in a dry, cool, and well-ventilated area.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Retention time corresponds to reference
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0% Any single impurity ≤ 0.5%
Water Content (KF)	≤ 1.0%
Residual Solvents (GC)	Complies with ICH Q3C guidelines
Heavy Metals	≤ 20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.